International Journal of Particle Therapy (IJPT) Update
Early Career Authors and the New IJPT Partnership with Elsevier
This January, the Particle Therapy Co-Operative Group (PTCOG) and the International Journal of Particle Therapy (IJPT) were pleased to announce IJPT’s new publishing partnership with Elsevier.
The collaboration offers many benefits for PTCOG Early Career authors, as it will greatly enhance IJPT’s journal reach and impact. Founded in 1880, Elsevier is part of the RELX Group, a publicly traded company headquartered in Amsterdam with worldwide offices. The company’s robust academic publishing presence; multiple peripheral marketing and advertising services; ownership of, and direct support for, Aries, IJPT’s current Editorial Manager peer review system; and access to PlumX Metrics, incorporated into its Scopus, ScienceDirect, Pure, Digital Commons and SSRN research products represent just a few of the advantages available to journal partners.
These advantages bolster PTCOG’s and IJPT Editorial Board efforts to assure that the journal provides an efficient means for dissemination of peer-reviewed information regarding particle therapy; becomes the preferred location for publication of all types of information regarding particle therapy; enhances the quality of particle therapy publications through dedicated and creative editorial assistance; facilitates career development of young particle therapy investigators; and embraces all aspects of diversity by welcoming multiple approaches and points of view that foster diversity and inclusion in research, writing, and review, while mitigating bias.
In addition, IJPT received its first Impact Factor of 1.7 last June and continues to maintain a strong 3.9 CiteScore, placing it in the 58th percentile among journals in the Radiology, Nuclear Medicine and Imaging category. For perspective on this ranking, the CiteScores for Practical Radiation Oncology and Advances in Radiation Oncology are 4.6 (67th percentile), and 4.5 (65th percentile), respectively. And while IJPT readership is relatively small (particle therapy accounts for <1% of radiation facilities and ≤2% of radiation treatments in the US and <1% across the globe), IJPT Impact Metrics and overall readership are expected to steadily improve as an Elsevier journal.
The new IJPT website is featured on Elsevier’s ScienceDirect publishing platform, considered to be one of the world’s largest, attracting approximately 19 million unique visitors each month. To submit your manuscript for consideration, visit the IJPTIJPT Editorial Manager website.
Nancy Mendenhall, Editor-in-Chief IJPT
*****************************************